Rohto Pharmaceutical - Public Comps and Valuation Multiples

Rohto Pharmaceutical Overview

About Rohto Pharmaceutical

Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.

Founded

1949

HQ

Employees

10.9K+

Website

rohto.co.jp

Sectors

Health & Beauty
Nutraceuticals & Cosmeceuticals
BioTech

Financials

LTM Revenue $2.1B

LTM EBITDA $350M

EV

$3.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Rohto Pharmaceutical Financials

As of December 2025, Rohto Pharmaceutical reported last 12-month revenue of $2.1B and EBITDA of $350M.

In the same period, Rohto Pharmaceutical generated $1.2B in LTM gross profit and $210M in net income.

See Rohto Pharmaceutical valuation multiples based on analyst estimates

Rohto Pharmaceutical P&L

In the most recent fiscal year, Rohto Pharmaceutical reported revenue of $2.0B and EBITDA of $361M.

Rohto Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Rohto Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$2.1B	XXX	$2.0B	XXX	XXX	XXX
Gross Profit	$1.2B	XXX	$1.1B	XXX	XXX	XXX
Gross Margin	55%	XXX	57%	XXX	XXX	XXX
EBITDA	$350M	XXX	$361M	XXX	XXX	XXX
EBITDA Margin	17%	XXX	18%	XXX	XXX	XXX
EBIT	$256M	XXX	$249M	XXX	XXX	XXX
EBIT Margin	12%	XXX	13%	XXX	XXX	XXX
Net Profit	$210M	XXX	$199M	XXX	XXX	XXX
Net Margin	10%	XXX	10%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Rohto Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.1B. EBITDA for the last twelve months was $350M. In the most recent fiscal year, Rohto Pharmaceutical achieved $2.0B in revenue and $361M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$2.1B	Analyst estimates available to subscribers	$2.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.2B	Analyst estimates available to subscribers	$1.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	54.7% gross margin	Analyst estimates available to subscribers	56.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$350M	Analyst estimates available to subscribers	$361M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	16.5% EBITDA margin	Analyst estimates available to subscribers	18.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$256M	Analyst estimates available to subscribers	$249M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	12.1% EBIT margin	Analyst estimates available to subscribers	12.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$210M	Analyst estimates available to subscribers	$199M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	9.9% net profit margin	Analyst estimates available to subscribers	10.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Rohto Pharmaceutical

This financial data table provides comprehensive performance metrics for Rohto Pharmaceutical, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Rohto Pharmaceutical generated $2.1B in revenue over the last twelve months.
The company achieved $350M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.2B.
Net income over the last twelve months reached $210M.

Fiscal Year Performance

In the most recent fiscal year, Rohto Pharmaceutical reported $2.0B in total revenue.
Fiscal year EBITDA was $361M.
The company maintained a gross profit margin of 56.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 18.3%.
Net profit margin reached 10.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Rohto Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Rohto Pharmaceutical Stock Performance

Rohto Pharmaceutical has current market cap of JPY 594B (or $3.8B), and EV of JPY 563B (or $3.6B).

Market Cap Evolution

Rohto Pharmaceutical Stock Data

As of January 1, 2026, Rohto Pharmaceutical's stock price is JPY 2628 (or $17).

See Rohto Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.6B	$3.8B	XXX	XXX	XXX	XXX	$0.91

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Rohto Pharmaceutical Valuation Multiples

Rohto Pharmaceutical's trades at 1.7x EV/Revenue multiple, and 10.1x EV/EBITDA.

See valuation multiples for Rohto Pharmaceutical and 15K+ public comps

Rohto Pharmaceutical Financial Valuation Multiples

As of January 1, 2026, Rohto Pharmaceutical has market cap of $3.8B and EV of $3.6B.

Equity research analysts estimate Rohto Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Rohto Pharmaceutical has a P/E ratio of 18.1x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$3.8B	XXX	$3.8B	XXX	XXX	XXX
EV (current)	$3.6B	XXX	$3.6B	XXX	XXX	XXX
EV/Revenue	1.7x	XXX	1.7x	XXX	XXX	XXX
EV/EBITDA	10.3x	XXX	10.1x	XXX	XXX	XXX
EV/EBIT	14.1x	XXX	14.1x	XXX	XXX	XXX
EV/Gross Profit	3.1x	XXX	n/a	XXX	XXX	XXX
P/E	18.1x	XXX	18.1x	XXX	XXX	XXX
EV/FCF	45.4x	XXX	17.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Rohto Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Rohto Pharmaceutical Margins & Growth Rates

Rohto Pharmaceutical's last 12 month revenue growth is 6%

Rohto Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Rohto Pharmaceutical's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Rohto Pharmaceutical's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Rohto Pharmaceutical and other 15K+ public comps

Rohto Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	6%	XXX	5%	XXX	XXX	XXX
EBITDA Margin	17%	XXX	17%	XXX	XXX	XXX
EBITDA Growth	7%	XXX	3%	XXX	XXX	XXX
Rule of 40	24%	XXX	23%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	32%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	19%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	44%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial